| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Tranylcypromine hemisulfate, also known as 2-PCPA, is a nonselective and irreversible monoamine oxidase inhibitor, which inhibits CYP2A6 with Ki of 0.08 μM and 0.2 μM in cDNA-expressing microsomes and Human Liver Microsomes, respectively. Tranylcypromine is used as an antidepressant and anxiolytic agent in the clinical treatment of mood and anxiety disorders, respectively.
| ln Vitro |
Independent of glial cells, tranylcypromine (10 nM to 10 μM) has neuroprotective benefits against toxicity generated by human Aβ (1-42) oligomers. RGCs are considerably shielded from both oxidative stress- and glutamate neurotoxicity-induced apoptosis by tranylcypromine (100 μM). Under glutamate (Glu)-induced stress circumstances, tranylcypromine increases the expression of mitogen-activated protein kinase 12 (p38 MAPKγ). Furthermore, tranylcypromine alters p38 MAPKγ activity to increase RGC survival [3].
|
||
|---|---|---|---|
| ln Vivo |
Tranylcypromine treatment improved dose-dependent generalized hyperalgesia and significantly and significantly decreased lesion size in mice with induced endometriosis. Additionally, treatment with tranylcypromine decreases immune reactivity to biomarkers like angiogenesis, proliferation, and H3K4 methylation, which causes EMT and inhibits the growth of lesions [2]. After NMDA-induced retinal injury, tranylcypromine hemisulfate (500 mM) injection inhibits morphological changes in the rat retina, inhibits caspase 3 activity, and restores p38 MAPKγ in the retina. These neuroprotective effects are observed on intracellular apoptosis signaling pathways. expression, and reduces the neurotoxicity of NMDA to increase the survival rate of RGCs following retinal damage [3]. BrdU immunohistochemistry revealed that tranylcypromine hemisulfate (10 μg/g) caused an approximate and significant doubling of labeled cells in the combined brain regions examined. The most significant increase in cerebellar cell proliferation is caused by tranylcypromine [4].
|
||
| Animal Protocol |
|
||
| References |
[1]. Caraci F, et al. Neuroprotective effects of the monoamine oxidase inhibitor tranylcypromine and its amide derivatives against Aβ(1-42)-induced toxicity. Eur J Pharmacol. 2015 Oct 5;764:256-263.
[2]. Sun Q, et al. Tranylcypromine, a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis. Reprod Biol Endocrinol. 2016 Apr 9;14:17. [3]. Tsutsumi T, et al. Potential Neuroprotective Effects of an LSD1 Inhibitor in Retinal Ganglion Cells via p38 MAPK Activity. Invest Ophthalmol Vis Sci. 2016 Nov 1;57(14):6461-6473. [4]. Romanczyk TB, et al. The antidepressant tranylcypromine alters cellular proliferation and migration in the adult goldfish brain. Anat Rec (Hoboken). 2014 Oct;297(10):1919-26 |
| Molecular Formula |
C9H12NO₂S₀.₅
|
|
|---|---|---|
| Molecular Weight |
182.23
|
|
| CAS # |
13492-01-8
|
|
| Related CAS # |
Tranylcypromine hydrochloride;1986-47-6;Tranylcypromine;155-09-9
|
|
| SMILES |
N[C@H]1[C@H](C2=CC=CC=C2)C1.[0.5H2SO4]
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 20 mg/mL (109.75 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.4876 mL | 27.4379 mL | 54.8757 mL | |
| 5 mM | 1.0975 mL | 5.4876 mL | 10.9751 mL | |
| 10 mM | 0.5488 mL | 2.7438 mL | 5.4876 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|---|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
